Influenza Viruses


Influenza viral infections cause a broad array of respiratory illnesses that are responsible for significant morbidity and mortality in children during seasonal epidemics . Influenza A viruses also have the potential to cause global pandemics , which can happen when a new (novel) influenza A virus emerges and transmits efficiently from person to person.

Etiology

Influenza viruses are large, single-stranded RNA viruses belonging to the family Orthomyxoviridae, which includes three genera (or types): A, B, and C. Influenza A and B viruses are the primary human pathogens causing seasonal epidemics, while influenza virus type C is a sporadic cause of predominantly mild upper respiratory tract illness. Influenza A viruses are further divided into subtypes based on two surface proteins that project as spikes from the lipid envelope, the hemagglutinin (HA) and neuraminidase (NA) proteins ( Fig. 285.1 ). Strain variants are identified by antigenic differences in their HA and NA and are designated by the geographic area from which they were originally isolated, isolate number, and year of isolation—for example, influenza A/Victoria/361/2011(H3N2). The HA and NA antigens from influenza B and C viruses do not receive subtype designations, as there is less variation among influenza B and C antigens. However, influenza B viruses can be further broken down into lineages; currently circulating influenza B viruses belong to the B/Yamagata or B/Victoria lineage.

Fig. 285.1, Graphical representation of influenza virus.

Epidemiology

Influenza has generally been thought to be transmitted primarily via respiratory droplets, but transmission through contact with secretions and small-particle aerosols may also occur. The typical incubation period ranges from 1 to 4 days, with an average of 2 days. Healthy adults are generally considered potentially infectious from a day before symptoms develop until 5-7 days after becoming ill. Children with primary influenza infection have higher influenza viral loads and more prolonged viral shedding than adults; therefore children may be able to infect others for a longer time. Influenza outbreaks occur commonly in schools and childcare settings. Healthcare-associated influenza infections can also occur in healthcare settings, and outbreaks in long-term care facilities and hospitals may cause significant morbidity.

In the United States, seasonal influenza viruses can be detected year round, but circulating viruses are most common during the fall and winter. Transmission through a community is rapid, with the highest incidence of illness occurring within 2-3 wk of introduction.

Antigenic Variation

Influenza A and B viruses contain a genome consisting of 8 single-stranded RNA segments. Minor changes within a subtype continually occur through point mutations during viral replication, particularly in the HA gene, and result in new influenza strains of the same HA type. This phenomenon, termed antigenic drift , occurs in both influenza A and B viruses. Variation in antigenic composition of influenza virus surface proteins occurs almost yearly, which confers a selective advantage to a new strain and contributes to annual epidemics. For this reason, the formulation of the influenza vaccine is reviewed each year and updated as needed.

Less frequent but more dramatic, major changes in virus subtype can occur, resulting in a new influenza A subtype to which most people have little to no immunity. This process is called antigenic shift and can occur through reassortment of viral gene segments when there is simultaneous infection by more than one strain of influenza in a single host, or by direct adaptation of an animal virus to a human host. Antigenic shift occurs in influenza A viruses, which have multiple avian and mammalian hosts acting as reservoirs for diverse strains.

Through the process of reassortment , potentially any of 18 HA and 11 NA proteins currently known to reside in influenza A viruses of nonhuman hosts could be introduced into humans, who may have little existing immunologic cross protection to emerging viruses. A global pandemic can result if an influenza A virus with a novel HA or NA enters a nonimmune human population and acquires the capacity for sustained and efficient transmission between people. Four major global pandemics have occurred since 1900: in 1918 caused by an influenza A(H1N1) virus, 1957 caused by an influenza A(H2N2) virus, 1968 caused by an influenza A(H3N2) virus, and 2009 caused by an influenza A virus designated A(H1N1)pdm09. The most severe pandemic in recorded history occurred in 1918, when the virus was estimated to have killed at least 50 million people. The 1918 pandemic virus was likely the result of direct adaptation of an avian influenza virus to the human host, rather than from reassortment. The 2009 pandemic virus stemmed from reassortment of genes from swine, avian, and human viruses ( Fig. 285.2 ). This resulted in the emergence of a novel influenza A(H1N1)pdm09 virus that spread quickly from North America across the globe and replaced the previously circulating seasonal H1N1 viruses.

Fig. 285.2, Host and lineage origins for the gene segments of the 2009 A(H1N1) virus.

Several novel influenza viruses, all originating in animals, have also caused outbreaks of human infections. Avian influenza A(H5N1), a virulent avian influenza virus that was first identified in 1997, has caused more than 800 documented cases in 16 countries, with a mortality rate over 50%. Another novel avian influenza, A(H7N9) virus, has caused more than 1,300 documented cases and also appears highly virulent. This virus first caused an outbreak of human infections in China during the spring of 2013, with annual epidemics in China occurring in subsequent years. During the first 4 yearly epidemics, infection was fatal in approximately 40% of documented cases.

In addition, novel influenza A variant viruses have caused human infections ( Table 285.1 ). These include H3N2v viruses, which caused 372 confirmed human infections in the United States from 2011 to 2016 and were primarily transmitted through swine contact at agricultural fairs. Influenza viruses that normally circulate in swine are designated variant (“v”) viruses when detected in humans, and H3N2v and other variant viruses, including H1N1v and H1N2v, have sporadically infected humans. In contrast to avian influenza A(H5N1) and A(H7N9) viruses, variant viruses generally cause mild illness and have been primarily detected in children. However, none of these viruses has exhibited sustained, efficient human-to-human transmission.

Table 285.1
Subtypes of Novel Influenza A Viruses and Clinical Syndromes in Human Infections
From Uyeki TM, Katz JM, Jernigan DB: Novel influenza A viruses and pandemic threats, Lancet 389:2172–2174, 2017.
LPAI VIRUSES HPAI VIRUSES VARIANT VIRUSES *
Conjunctivitis H7N2, H7N3, H7N7, H10N7 H7N3, H7N7 H1N1v, H3N2v
Upper respiratory tract illness H6N1, H7N2, H7N3, H7N9, H9N2, H10N7 H5N1, H5N6, H7N7 H1N1v, H1N2v, H3N2v
Lower respiratory tract disease, pneumonia H7N2, H7N9, H9N2, H10N8 H5N1, H5N6, H7N7, H7N9 H1N1v, H3N2v
Respiratory failure, acute respiratory distress syndrome H7N9, H10N8 H5N1, H5N6, H7N7, H7N9 H1N1v, H3N2v
Multiorgan failure H7N9, H10N8 H5N1, H5N6, H7N7, H7N9
Encephalopathy or encephalitis H7N9 H5N1
Fatal outcomes H7N9, H9N2, H10N8 H5N1, H5N6, H7N7, H7N9 H1N1v, H3N2v
LPAI, low-pathogenic avian influenza; HPAI, highly pathogenic avian influenza.

* Variant viruses of swine origin.

High mortality in reported cases: about 40% for LPAI H7N9, about 50% for HPAI H5N1, and about 70% for HPAI H5N6.

Seasonal Influenza

An estimated 11,000-45,000 children younger than 18 yr of age are hospitalized annually in the United States as a result of seasonal influenza-associated complications, with approximately 6,000-26,000 hospitalizations in children younger than 5 yr of age. Since 2004, the annual number of reported influenza-associated pediatric deaths in the United States has ranged from 37 to 171 during regular influenza seasons (358 were reported to have occurred during the 2009 H1N1 pandemic). Influenza disproportionately affects children with specific chronic conditions, such as underlying pulmonary, cardiac, or neurologic and neuromuscular disorders. Very young children, especially those younger than 2 yr of age, and children with chronic medical conditions are more likely to develop severe influenza-related complications, including viral and bacterial pneumonia, hospitalization, respiratory failure, and death. However, while children with underlying medical conditions are at higher risk of complications, many healthy children are hospitalized with influenza, and nearly half of pediatric influenza-associated deaths are in children that have no known underlying medical condition.

Influenza also causes a substantial burden of disease in outpatient settings. It contributes to an estimated 600,000 to 2,500,000 outpatient medical visits annually in children younger than 5 yr of age, and has been identified in 10–25% of outpatient visits among all children with respiratory symptoms during influenza season. Influenza may also be underdiagnosed. Many who seek medical care for influenza do not have laboratory testing performed and do not receive a diagnosis of influenza. Every year, 3-4 influenza virus types or subtypes typically co-circulate, including influenza A(H3N2), influenza A(H1N1), and B viruses. Although 1 subtype usually predominates in any given season, it is difficult to predict which will be predominant. Thus, the influenza vaccine varies annually and contains 3 or 4 antigens representing the expected circulating types.

Pathogenesis

Influenza viruses infect the respiratory tract epithelium, primarily the ciliated columnar epithelial cells, by using the HA to attach to sialic acid residues. After viral entry into cells, virus replication occurs usually within 4-6 hr, and new virus particles are assembled and released to infect neighboring cells. With primary infection, virus replication continues for 10-14 days. Influenza virus causes a lytic infection of the respiratory epithelium with loss of ciliary function, decreased mucus production, and desquamation of the epithelial layer. These changes permit secondary bacterial invasion, either directly through the epithelium or, in the case of the middle ear space, through obstruction of the normal drainage through the eustachian tube.

The exact immune mechanisms involved in termination of primary infection and protection against reinfection are complex. Induction of cytokines that inhibit viral replication, such as interferon and tumor necrosis factor, as well as other host defenses, such as cell-mediated immune responses and local and humoral antibody defenses, all likely play a role. Secretory immunoglobulin A antibodies produced by the respiratory mucosa are thought to be an effective and immediate response generated during influenza infection. Serum antibody levels inhibiting HA activity can usually be detected by the second week after infection. These antibodies are also generated by vaccines, and high HA inhibition titers correlate with protection.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here